Kineta Presents New Preclinical Data On Lead Anti-CD27 Agonist Antibody At AACR Special Conference On Tumor Immunology And Immunotherapy
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA) has presented new preclinical data on its anti-CD27 agonist monoclonal antibodies (mAbs) in development for the treatment of advanced solid tumors. The data was presented at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The company's leading mAb candidates showed high affinity binding to both human and cynomolgus monkey CD27, with no cross-reactivity detected against other members of the tumor necrosis factor receptor super family (TNFRSF).
October 04, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta's new preclinical data on its anti-CD27 mAbs for treating advanced solid tumors could potentially boost investor confidence in the company's research and development capabilities.
The new preclinical data presented by Kineta shows promising results for its anti-CD27 mAbs in treating advanced solid tumors. This could potentially boost investor confidence in the company's research and development capabilities, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100